Elanco Animal Health Inc
ELAN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELAN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELAN
Elanco Animal Health Inc is a global animal health company that develops, manufactures, and markets pet health and livestock products, with a diversified portfolio and a focus on innovation.
Key risk: Highly competitive industry
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$12.05B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Elanco Animal Health Inc is a global animal health company that develops, manufactures, and markets pet health and livestock products, with a diversified portfolio and a focus on innovation.
- Elanco operates in over 90 countries with approximately 9,900 employees and 16 manufacturing sites [sec · filed 2026-04-08].
- Revenue for the year ended December 31, 2025 was $4,715 million, a 6% increase from $4,439 million in 2024 [sec_mda · as of 2026-02-24].
- As of June 30, 2026, the company reported cash and equivalents of $530.0 million, total revenue of $1,368.0 million, and net income of $54.0 million [latest reported financials].
- The company has launched a diverse portfolio of innovation, including one new blockbuster and five potential blockbusters now in market [sec · filed 2025-03-27].
- 53% of revenue comes from outside the U.S., indicating a strong international presence [sec · filed 2026-04-08].
What works
- Elanco has a diversified portfolio of pet health and livestock products, with a presence in over 90 countries, providing geographic and product diversification [sec · filed 2026-04-08].
- The company has launched a new blockbuster and five potential blockbusters, indicating a strong pipeline and innovation focus [sec · filed 2025-03-27].
- Revenue grew 6% year-over-year in 2025, from $4,439 million to $4,715 million, showing top-line growth [sec_mda · as of 2026-02-24].
- As of March 31, 2026, the company had $428 million in cash and $750 million in unused borrowing capacity on its Revolving Credit Facility, providing liquidity [sec_mda · as of 2026-05-06].
What to weigh
- The company operates in a highly competitive industry, with risks from disruptive innovations and advances in veterinary medical practices [sec · filed 2026-04-08].
- Cash used for investing activities increased to $170 million for the six months ended June 30, 2026, from $114 million in the prior year, partly due to the AHV acquisition [sec_mda · as of 2026-08-05].
- The company has significant debt, with total debt of $3,845.0 million as of June 30, 2026, which may impact financial flexibility [latest reported financials].
- Competition from generic products that may be viewed as more cost-effective poses a risk to market share and pricing [sec · filed 2026-04-08].
From the filings
Quoted directly from source documents.
Elanco has a global presence with operations in over 90 countries and approximately 9,900 employees.
“~9,900Employees Worldwide | ~1,900Sales Representatives | 1,000+R&DEmployees | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Diversified Portfolioof pet health and livestock products | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1, 2Non-GAAP financial measure. See Appendix A for more information, including GAAP to non-GAAP reconciliations.* Facts and figures shown are as of Dec. 31, 2025.”
SEC filings · April 8, 2026
Revenue grew 6% year-over-year in 2025.
“Revenue | | $ | 4,715 | | | $ | 4,439 | | | 6%”
SEC MD&A · February 24, 2026
The company has launched a new blockbuster and five potential blockbusters.
“Launched diverse portfolio of Innovation with one new blockbuster and five potential blockbusters now in market”
SEC filings · March 27, 2025
As of March 31, 2026, Elanco had $428 million in cash and $750 million in unused borrowing capacity.
“As of March 31, 2026, we had cash and cash equivalents of $428 million and unused borrowing capacity on our Revolving Credit Facility of approximately $750 million.”
SEC MD&A · May 6, 2026
Risks & what to watch (4)›
Key risks
- Highly competitive industry — Elanco operates in a highly competitive industry with risks from disruptive innovations and advances in veterinary practices [sec · filed 2026-04-08].
- Generic product competition — Competition from generic products that may be viewed as more cost-effective could impact market share [sec · filed 2026-04-08].
- High debt levels — Total debt of $3,845.0 million as of June 30, 2026 may constrain financial flexibility and increase interest costs [latest reported financials].
- R&D and regulatory approval risks — Success of R&D and regulatory approval efforts is uncertain and could affect pipeline and revenue [sec · filed 2026-04-08].
What to watch
- Monitor the performance of the new blockbuster and five potential blockbusters launched in the market [sec · filed 2025-03-27].
- Watch for updates on the integration and impact of the AHV acquisition, which involved $76 million paid in April 2026 [sec_mda · as of 2026-08-05].
- Track changes in debt levels and liquidity, including cash position and borrowing capacity, given total debt of $3,845.0 million [latest reported financials].
- Observe revenue growth trends, especially international revenue which accounts for 53% of total [sec · filed 2026-04-08].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Elanco Animal Health Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Elanco Animal Health Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 1.06 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
512
Total value held
$12.30B
| Holder | Shares | Value |
|---|---|---|
| dodge & cox | 68,944,100 | $1.65B |
| fmr llc | 50,925,366 | $1.22B |
| blackrock, inc. | 47,622,630 | $1.14B |
| primecap management co/ca/ | 45,840,956 | $1.10B |
| vanguard capital management llc | 44,672,248 | $1.07B |
| dimensional fund advisors lp | 24,527,135 | $586.9M |
| vanguard portfolio management llc | 22,637,357 | $541.7M |
| state street corp | 15,336,479 | $367.0M |
| geode capital management, llc | 11,192,404 | $267.9M |
| black creek investment management inc. | 10,493,849 | $251.1M |
Showing top 10 of 512 institutional holders of Elanco Animal Health Inc. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 7.8%
- Days to cover
- 4.1
- Shares short
- 24,563,390
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELAN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Elanco Animal Health Inc?
Elanco Animal Health Inc is a global animal health company that develops, manufactures, and markets pet health and livestock products, with a diversified portfolio and a focus on innovation.
Who is the CEO of Elanco Animal Health Inc?
Mr. Jeffrey N. Simmons is the chief executive officer of Elanco Animal Health Inc (ELAN).
Where is Elanco Animal Health Inc headquartered?
Elanco Animal Health Inc (ELAN) is headquartered in Indianapolis, IN, United States.
What therapeutic areas does Elanco Animal Health Inc focus on?
Elanco Animal Health Inc develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.